ArticleCancer cell international2025
miR-652-5p promoter hypermethylation enhances glioblastoma malignancy through the SDC1/TGFβ2/pERBB4 complex via HIF2α-mediated regulation under hypoxia.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor exosomes impact functional hallmarks of cancer.Cancer metastasis reviews · 2026Review
- MicroRNAs in Esophageal Cancer: Implications for Diagnosis, Progression, Prognosis and Chemoresistance.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is highly malignant, and hypoxia often exacerbates its aggressiveness. The aim of this study was to explore the molecular mechanism by which miR-652-5p promoter hypermethylation augments the malignancy of glioblastoma under hypoxic conditions.
methodsThis study combined data from public glioma databases, clinical tissue analysis, and cellular assays. Techniques such as RT‒qPCR, western blotting, miRNA sequencing, and ELISA were used to assess the impact of miR-652-5p under hypoxic conditions. A BALB/c-nu mouse model injected with GBM cells was used for in vivo evaluation.
resultsmiR-652-5p was markedly upregulated in HIF2α-knockout cells, with promoter hypermethylation linked to reduced methylation post-knockout. Inhibition of miR-652-5p upregulated SDC1, SDC1-Intra, and TGFβ2 expression. Live-cell imaging and fluorescence staining revealed the role of SDC1 in exosome-mediated TGFβ2 secretion. SDC1 knockdown reduced exosome release and TGFβ2 secretion and confirmed the binding of TGFβ2 to SDC1/sSDC1 via HS chains and to ERBB4 on recipient cells. Downregulation of SDC1 and TGFβ2 expression decreased the levels of PI3K, PDK1, p-PDK1, AKT, p-AKT, and mTOR, weakened tumorigenic properties, and extended OS. In vivo results from a nude mouse model supported these findings.
conclusionsUnder hypoxic conditions, miR-652-5p promoter hypermethylation promotes GBM malignancy via the SDC1/TGFβ2/pERBB4 axis in a HIF2α-dependent manner. Understanding this mechanism may lead to the development of epigenetic treatments and personalized medical approaches to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.